You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 4,329,356


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,329,356
Title: Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
Abstract:Fluoxetine alone or a combination of fluoxetine and l-5-hydroxytryptophan, preferably also with a peripheral decarboxylase inhibitor, is administered to hypertensive mammals to lower blood pressure.
Inventor(s): Holland; Donald R. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:06/202,847
Patent Claims: 1. A method for lowering blood pressure in a hypertensive mammal in need of treatment which comprises the co-administration of hypotensively effective amounts of fluoxetine and l-5-hydroxytryptophane or pharmaceutically acceptable salts thereof, the amount of said combination administered being significantly effective to reduce the blood pressure of said hypertensive mammal, compared to each alone.

2. A process according to claim 1 in which the drugs are administered orally.

3. A process according to claim 2 in which fluoxetine is administered as a hydrochloride salt.

4. A process according to claim 3 in which the fluoxetine hydrochloride daily dosage level is 0.5-2 mg./kg. of mammalian body weight.

5. A process according to claim 2 in which the l-5-tryptophane daily dose level is from 3-40 mg/kg of mammalian body weight.

6. A method for lowering blood pressure in hypertensive mammals in need of treatment which comprises the co-administration of hypotensively-effective amounts of fluoxetine, and l-5-tryptophan or pharmaceutically acceptable salts thereof, the amount of said combination, compared to each alone, being significantly effective to reduce the blood pressure of said hypertensive mammals plus a peripheral decarboxylase inhibitor in an amount sufficient to prevent side effects attributable to serotonin.

7. A process according to claim 6 in which the drugs are administered orally.

8. A process according to claim 7 in which fluoxetine is administered as a hydrochloride salt.

9. A process according to claim 6 in which the peripheral decarboxylase inhibitor is carbidopa.

10. A process according to claim 8 in which the fluoxetine hydrochloride daily dose level is from 0.5-2.0 mg/kg of mammalian body weight.

11. A process according to claim 7 in which the l-5-tryptophan daily dose level is from 2-40 mg/kg of mammalian body weight.

12. A process according to claim 9 in which the daily carbidopa dose level if from 1-6 mg/kg of mammalian body weight.

13. A method for lowering blood pressure in hypertensive mammals in need of treatment which comprises the administration to such a mammal of an antihypertensive amount of fluoxetine or a pharmaceutically-acceptable salt thereof.

14. A process according to claim 13 in which fluoxetine or a pharmaceutically-acceptable salt thereof is administered by the oral route.

15. A process according to claim 13 in which fluoxetine hydrochloride is administered.

16. A process according to claim 13 in which the fluoxetine daily dose level is from 0.5-2.0 mg/kg of mammalian body weight.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.